Endothelial Function After Cardiac Surgery
Does Plasma Volume Replacement With 5% Human Albumin Reduce Endothelial Injury and Glycocalyceal Disruption Compared With 6% Hydroxyethylstarch (130/0.4) in Patients Having Cardiac Surgery? A Substudy of the SHARP Clinical Trial
Sponsor: The Cleveland Clinic
A NA clinical study on Endothelial Dysfunction, this trial is completed. The trial is conducted by The Cleveland Clinic and has accumulated 11 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Mar 2024 — Jul 2024 [monthly]
Completed NA
-
Jan 2021 — Mar 2024 [monthly]
Completed NA
-
Aug 2020 — Jan 2021 [monthly]
Completed NA
Status: Recruiting → Completed
▶ Show 6 earlier versions
-
Aug 2019 — Aug 2020 [monthly]
Recruiting NA
-
Sep 2018 — Aug 2019 [monthly]
Recruiting NA
-
Aug 2018 — Sep 2018 [monthly]
Recruiting NA
-
Jun 2018 — Aug 2018 [monthly]
Recruiting NA
-
Feb 2017 — Jun 2018 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The Cleveland Clinic
For direct contact, visit the study record on ClinicalTrials.gov .